Harm Reduction versus Promotion

Harm reduction developed in drug policy on a counterfactual: for a given person the realistic alternative to unsafe use is often not abstinence but the same behaviour conducted with less information. Needle and syringe programmes, opioid substitution and drug-checking services are its established forms, and their evidence base concerns transmission and overdose, not approval of the behaviour. The line separating it from promotion is not the topic discussed but the default the writing assumes and the capability it adds.

Applied to peptides the distinction becomes operational. Explaining that a research-labelled vial has no verified sterility, no endotoxin limit and no traceable batch is harm reduction: it changes a reader's estimate of risk without making anything possible that was not already possible. Publishing a reconstitution volume, a titration schedule or a combination is a protocol, and it stays a protocol regardless of the disclaimer above it.

The usable test is counterfactual and capability-based. Ask whether the information is usable only by someone already committed, and whether withholding it would prevent harm or only prevent understanding. Describing why a stated purity figure does not bound endotoxin content prevents nothing and clarifies much. Supplying numbers a person can act on transfers capability directly, and the sincerity of the surrounding warning has no bearing on that.

Both failure modes are common. The first is harm reduction as cover: a page opening with a disclaimer and then listing doses, schedules and suppliers is promotional material wearing a safety label, and the header changes nothing about what the page enables. The second is the mirror image, treating any discussion of mechanism or risk as encouragement, which strips careful sources out of the reading list and leaves the reader with forums that never had an editorial line.